Contrave Launch Strategy: Comfortable Drug To Combat Effects Of Comfort Food
Executive Summary
Orexigen and marketing partner Takeda’s efforts “will be scaled like a typical diabetes launch,” making it much larger than other recent obesity launches.
You may also be interested in...
Arena Looking To Puff Up Belviq Sales With Smoking Indication
Arena’s Belviq has failed to gain much traction in the obesity market, but the biotech is hoping a smoking-cessation indication could help bolster sales.
Pink Sheet Podcast: Relyvrio And Public Promises, Allergy Biomarker Adcomms, PMDA In The USA
Pink Sheet reporters and editor discuss the implications of Amylyx following through on its pledge to remove Relyvrio from the market after its trial failed, an FDA idea to bring potential biomarkers for promising allergy and asthma treatments to advisory committees, and Japan’s PMDA opening an office in Washington D.C.
Pink Sheet Podcast: Mifepristone And Misinformation At SCOTUS, Understanding US FDA’s ODAC
Pink Sheet reporters and editor discuss the upcoming US Supreme Court arguments on mifepristone access, the SCOTUS reaction to the fight against misinformation, and the FDA’s Oncologic Drugs Advisory Committee going against three negative product reviews.